EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer

Jinfeng Liu, Sijie Liu, Dan Li, Hongbin Li, Fan Zhang

Global Medical Genetics · 01.06.2024 · 11 (02) · 150-158

DOI: 10.1055/s-0044-1786004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Medical Genetics, erschienen am 01.06.2024. Verfasst von Jinfeng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

NFE2L2 (nuclear factor erythroid-2-related factor-2) encodes a basic leucine zipper (bZIP) transcription factor and exhibits variations in various tumor types, including lung cancer. In this study, we comprehensively investigated the impact of simultaneous mutations on the survival of NFE2L2-mutant lung cancer patients within specific subgroups.

Methods

A cohort of 1,103 lung cancer patients was analyzed using hybridization capture-based next-generation sequencing.

Results

The NFE2L2 gene had alterations in 3.0% (33/1,103) of lung cancer samples, including 1.5% (15/992) in adenocarcinoma and 16.2% (18/111) in squamous cell carcinoma. Thirty-four variations were found, mainly in exons 2 (27/34). New variations in exon 2 (p.D21H, p.V36_E45del, p.F37_E45del, p.R42P, p.E67Q, and p.L76_E78delinsQ) were identified. Some patients had copy number amplifications. Co-occurrence with TP53 (84.8%), CDKN2A (33.3%), KMT2B (33.3%), LRP1B (33.3%), and PIK3CA (27.3%) mutations was common. Variations of NFE2L2 displayed the tightest co-occurrence with IRF2, TERC, ATR, ZMAT3, and SOX2 (p < 0.001). In The Cancer Genome Atlas Pulmonary Squamous Carcinoma project, patients with NFE2L2 variations and 3q26 amplification had longer median survival (63.59 vs. 32.04 months, p = 0.0459) and better overall survival.

Conclusions

NFE2L2 mutations display notable heterogeneity in lung cancer. The coexistence of NFE2L2 mutations and 3q26 amplification warrants in-depth exploration of their potential clinical implications and treatment approaches for affected patients.

Schlagwörter

Stichwörter der Autor:innen

3q36 amplificationNFE2L2co-occurrence mutationslung cancernext-generation sequencing

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Thoracic Surgery, Beijing Aerospace General Hospital, Beijing, China.
  • Department of General Surgery, Jingxing County Hospital of Hebei Province, Shijiazhuang, China.
  • Department of Oncology, Rongcheng County People's Hospital, Baoding, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Zitieren

APA

Liu, J., Liu, S., Li, D., Li, H., & Zhang, F. (2024). Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer. Global Medical Genetics, 11(02), 150-158. https://doi.org/10.1055/s-0044-1786004

Vancouver

Liu J, Liu S, Li D, Li H, Zhang F. Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer. Global Medical Genetics. 2024;11(02):150-158. doi:10.1055/s-0044-1786004

BibTeX
@article{Liu2024,
  author = {Liu, Jinfeng and Liu, Sijie and Li, Dan and Li, Hongbin and Zhang, Fan},
  title = {Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer},
  journal = {Global Medical Genetics},
  year = {2024},
  volume = {11},
  number = {02},
  pages = {150--158},
  doi = {10.1055/s-0044-1786004}
}
Kostenlos starten →